An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens [0.03%]
β内酰胺- β内酰胺酶抑制剂联合疗法治疗碳青霉烯类耐药革兰阴性病原体的最新研究进展
Ilias Karaiskos,Aikaterini Gkoufa,Eudoxia Kyriazopoulou et al.
Ilias Karaiskos et al.
Introduction: Carbapenem-resistant Gram-negative bacteria represent a major global health threat driven by diverse β-lactamase enzymes, particularly KPC, metallo-β-lactamases, and OXA-type carbapenemases, leading to lim...
Optimizing tamoxifen therapy in breast cancer: a narrative review of dose escalation in patients with CYP2D6 polymorphisms [0.03%]
乳腺癌他莫昔芬治疗的优化：CYP2D6多态性患者的剂量递增叙事综述
Juliana Henrique Duarte,Jose Claudio Casali-da-Rocha,Rafael Linden et al.
Juliana Henrique Duarte et al.
Introduction: The efficacy of tamoxifen in breast cancer endocrine therapy may be compromised by factors such as low adherence, drug interactions, and polymorphisms in CYP2D6, which is essential for converting tamoxifen i...
Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a PBPK modeling approach [0.03%]
基于PBPK模型的联合使用利福平和克拉霉素对艾沙他韦/泰萨他韦/维卡他韦药代动力学影响研究
Madeline Sanders,Eunjin Hong,Manya Jain et al.
Madeline Sanders et al.
Background: Rifampin (RIF) is first-line therapy for Mycobacterium avium complex (MAC) in people with cystic fibrosis (CF); but it induces CYP3A, causing significant drug - drug interactions (DDIs) with elexacaftor/tezaca...
Gastrointestinal bleeding risk among antithrombotics users: a propensity score matched study of drug classes [0.03%]
抗凝药使用者的胃肠出血风险：药物种类的倾向得分匹配研究
Prajwal M Pradhan,Erich Kummerfeld,Steven Johnson et al.
Prajwal M Pradhan et al.
Background: Antithrombotic drug-drug interactions (DDIs) impact patient safety. This study used causal inference framework to examine the association between interacting drugs, direct oral anticoagulants (DOACs), antiplat...
Complex in vitro model developers' perspective on advanced hepatic in vitro culture methods for predictive drug safety [0.03%]
有关预测药物安全性的高级肝组织体外培养方法的复杂模型开发者的观点
Maria Vittoria Colombo,Anna Borgström,Bruno Guy Henri Filippi
Maria Vittoria Colombo
Introduction: Adverse drug reactions remain a major barrier to drug development, with hepatotoxicity representing a persistent cause of clinical failure, market withdrawal, and post marketing restrictions. Global surveys ...
Evaluation of the pharmacokinetics of emerging therapeutics for high grade glioma [0.03%]
高分级胶质瘤新兴治疗药物药代动力学的评估
Antonio Ruggiero
Antonio Ruggiero
Introduction: High-grade gliomas represent the most aggressive primary brain tumors with dismal prognosis despite multimodal treatment approaches. The blood-brain barrier poses a significant challenge for drug delivery, m...
Transplacental pharmacokinetics and developmental toxicity of chemotherapeutic agents: a comparative analysis of fetal and pediatric exposure profiles [0.03%]
化疗药物的胎盘药代动力学和发育毒性：胎儿与儿科暴露特征的比较分析
Antonio Ruggiero
Antonio Ruggiero
Introduction: Administering chemotherapy during pregnancy poses significant clinical challenges, requiring careful balance between effective maternal cancer treatment and protection of the developing fetus. Understanding ...
Citalopram serum concentrations in men and women of pre- and post-menopausal age [0.03%]
氟西汀在男女绝经前和绝经后的血药浓度
Eline L Bosch,Franciska de Beer,Danielle C Cath et al.
Eline L Bosch et al.
Background: Sex and reproductive life-stage are currently not considered in (es)citalopram prescription guidelines, despite evidence of sex-related differences in its pharmacokinetics, tolerability, and therapeutic respon...
Clinical, toxicological and pharmacokinetic data of emerging drugs for the treatment of atherosclerosis: are they promising? [0.03%]
用于治疗动脉粥样硬化的新型药物的临床、毒理和药代数据：前景如何？
Khaled Naja,Mohamed A Elrayess,Manfredi Rizzo
Khaled Naja
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies? [0.03%]
如何克服在进行复杂DDI研究时出现的药动学挑战？
Iain Gardner,Eva Gil Berglund,Hannah M Jones et al.
Iain Gardner et al.